Metsera Stock Jumps Nearly 60% After Pfizer Confirms $7.3 Billion Acquisition Deal

Metsera stock surged on Monday after Pfizer announced it will acquire the biotech firm in a multi-billion-dollar deal. The agreement values Metsera at up to $7.3 billion. Shares of Metsera rose almost 60% in pre-market trading, while Pfizer stock also ticked higher.

The deal will give Pfizer access to Metsera’s pipeline of obesity and cardiometabolic treatments. Pfizer will pay $47.50 per share in cash, a 43% premium on Friday’s close. If key trial milestones are met, shareholders could receive an extra $22.50 per share, pushing the value higher.

Metsera Stock and Pfizer Stock: Deal Details and Market Impact

The purchase of Metsera marks one of Pfizer’s largest recent moves. According to Reuters, the acquisition gives Pfizer four clinical-stage programs. These include injectable and oral GLP-1 receptor agonists and an amylin analog candidate. Such drugs are aimed at obesity and type 2 diabetes, both fast-growing treatment areas.

Metsera’s lead therapy MET-097i has already shown promising early trial data, with patients losing more than 11% of body mass in 12 weeks. Pfizer sees the potential to build on these results and expand its role in the global weight-loss drug market.

Pfizer’s own obesity candidate, Danuglipron, failed earlier this year in clinical testing. The acquisition of Metsera offers the company a fresh entry into a booming field led by Eli Lilly and Novo Nordisk. Analysts forecast the obesity drug market could reach nearly $95 billion annually by the next decade.

Investors welcomed the news. Metsera shares soared above $50 in early trading. Pfizer stock rose about 1–2%, showing cautious optimism from the market.

Why the Pfizer–Metsera Deal Matters for the Future

The deal is more than just another acquisition. For Pfizer, it is a strategic attempt to rebuild growth after COVID-19 vaccine sales fell sharply. Its stock has dropped nearly 50% since 2021 highs. Adding a strong obesity drug portfolio could restore confidence among investors.

For Metsera, the buyout provides global resources and funding to advance clinical programs faster. The company, which only recently went public, now secures a major partner with deep market reach.

Industry experts note that competition in weight-loss treatments is fierce. Pfizer will face rivals with established drugs already on the market. Still, Metsera’s diverse pipeline may offer unique advantages in safety and dosing.

Metsera stock and Pfizer stock will remain in focus in the coming weeks as investors weigh the long-term success of this high-stakes deal.

FYI (keeping you in the loop)-

Q1: Why did Metsera stock rise so sharply?

Metsera stock surged almost 60% because Pfizer agreed to acquire the company at a significant premium. The deal values Metsera at up to $7.3 billion.

Q2: How much is Pfizer paying per Metsera share?

Pfizer will pay $47.50 in cash per share. Additional payments of up to $22.50 per share could follow if clinical milestones are achieved.

Q3: What happens to Pfizer stock after the announcement?

Pfizer stock rose about 1–2% in pre-market trading. Investors see the deal as a chance to rebuild Pfizer’s pipeline and growth prospects.

Q4: What drugs is Metsera developing?

Metsera is developing GLP-1 receptor agonists and amylin analogs for obesity and diabetes. Early trials showed significant weight loss results.

Q5: When will the Pfizer–Metsera deal close?

The companies expect the deal to close in the fourth quarter of 2025. It depends on regulatory approval and standard closing conditions.

References

Reuters. (2025, September 22). Pfizer to acquire Metsera in multi-billion-dollar deal.

Financial Times. (2025, September 22). Pfizer seals up to $7.3bn takeover of weight loss drugmaker Metsera.

Bloomberg. (2025, September 22). Pfizer’s obesity bet with Metsera buyout.